Literature DB >> 23660012

Incidence of pseudotumor and acute lymphocytic vasculitis associated lesion (ALVAL) reactions in metal-on-metal hip articulations: a meta-analysis.

Kevin F Wiley1, Kai Ding, Julie A Stoner, David C Teague, Khalid M Yousuf.   

Abstract

We systematically reviewed the peer-reviewed literature to determine a pooled estimate of the incidence of pseudotumor and acute lymphocytic vasculitis associated lesions (ALVAL) in adult patients with primary metal-on-metal (MoM) total hip arthroplasty or resurfacing. Fourteen eligible articles were identified, with a total of 13,898 MoM hips. The incidence of pseudotumor/ALVAL ranged from 0% to 6.5% of hips with a mean follow-up ranging from 1.7 to 12.3 years across the studies. The pooled estimated incidence of pseudotumor/ALVAL is 0.6% (95% CI: 0.3% to 1.2%). The rate of revision for any reason ranged from 0% to 14.3% of hips, with a pooled estimate of 3.9% (95% CI: 2.7% to 5.3%).
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALVAL; hip arthroplasty; hip resurfacing; hypersensitivity; metal-on-metal; pseudotumor

Mesh:

Substances:

Year:  2013        PMID: 23660012     DOI: 10.1016/j.arth.2013.03.027

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  21 in total

Review 1.  What are the advantages and disadvantages of imaging modalities to diagnose wear-related corrosion problems?

Authors:  Denis Nam; Robert L Barrack; Hollis G Potter
Journal:  Clin Orthop Relat Res       Date:  2014-03-25       Impact factor: 4.176

2.  Heavy metal? Recognizing complications of metal on metal hip arthroplasty.

Authors:  Denise M Millstine; Hannah J Hakes; Anita P Mayer; Mark J Spangehl
Journal:  J Womens Health (Larchmt)       Date:  2014-06-16       Impact factor: 2.681

3.  [Complications of metal-on-metal tribological pairing].

Authors:  M Stiehler; F Zobel; F Hannemann; J Schmitt; J Lützner; S Kirschner; K-P Günther; A Hartmann
Journal:  Orthopade       Date:  2014-01       Impact factor: 1.087

4.  Patient-Reported Outcomes After Revision of Metal-on-Metal Total Bearings in Total Hip Arthroplasty.

Authors:  Ana Mata-Fink; Daniel J Philipson; Benjamin J Keeney; Dipak B Ramkumar; Wayne E Moschetti; Ivan M Tomek
Journal:  J Arthroplasty       Date:  2016-10-11       Impact factor: 4.757

5.  Do alumina matrix composite bearings decrease hip noises and bearing fractures at a minimum of 5 years after THA?

Authors:  Seung-Hoon Baek; Won Keun Kim; Jun Young Kim; Shin-Yoon Kim
Journal:  Clin Orthop Relat Res       Date:  2015-12       Impact factor: 4.176

6.  What Is the Clinical Presentation of Adverse Local Tissue Reaction in Metal-on-metal Hip Arthroplasty? An MRI Study.

Authors:  Vincent P Galea; Inari Laaksonen; James W Connelly; Sean J Matuszak; Marc Nortje; Rami Madanat; Orhun Muratoglu; Henrik Malchau
Journal:  Clin Orthop Relat Res       Date:  2019-02       Impact factor: 4.176

7.  Pseudotumor associated with cemented bipolar hemiarthroplasty: an unusual presentation as a granulomatous thigh mass.

Authors:  Tomohiro Goto; Kazuaki Mineta; Tomoya Takasago; Daisuke Hamada; Koichi Sairyo
Journal:  Skeletal Radiol       Date:  2015-06-23       Impact factor: 2.199

Review 8.  Do retrieval analysis and blood metal measurements contribute to our understanding of adverse local tissue reactions?

Authors:  Patricia A Campbell; Michael S Kung; Andrew R Hsu; Joshua J Jacobs
Journal:  Clin Orthop Relat Res       Date:  2014-12       Impact factor: 4.176

Review 9.  Osteoporosis and orthopedic surgery: effect of bone health on total joint arthroplasty outcome.

Authors:  Linda A Russell
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

10.  Risk factors and modes of failure in the modern dual mobility implant. A systematic review and meta-analysis.

Authors:  Fu-Yuan Pai; Hsuan-Hsiao Ma; Te-Feng Arthur Chou; Tsan-Wen Huang; Kuo-Chin Huang; Shang-Wen Tsai; Cheng-Fong Chen; Wei-Ming Chen
Journal:  BMC Musculoskelet Disord       Date:  2021-06-14       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.